Ashish Saxena, MD, PhD Discusses Immunotherapy Drugs Effect on OS in Lung Cancer
Ashish Saxena, MD, PhD, from Weill Cornell Medicine, discussed how immunotherapy may lead to an increase in overall survival of patients at the Annual New York Lung Cancers Symposium®.
Ashish Saxena, MD, PhD, from Weill Cornell Medicine, discussed how neoadjuvant and adjuvant immunotherapy may lead to an increase in overall survival of patients with lung cancer at the Annual New York Lung Cancers Symposium®.
Transcription:
So, I think we’re most excited about moving the immunotherapy drugs to earlier lines of therapy, and sort of increasing the chances of cure from lung cancer. And so, I’m excited to see the studies with, you know, neoadjuvant immunotherapy and adjuvant immunotherapy and how they may play out in terms of increasing the overall survival of patients.
Neoadjuvant Capecitabine Plus Temozolomide in Atypical Lung NETs
Read about a woman with well-differentiated atypical carcinoid who experienced a 21% regression in primary tumor size after 12 months on neoadjuvant capecitabine and temozolomide.
